
    
      A total of 60 patients with hypertension and acute ischemic stroke (clinic BP >160/100 mmHg
      and <220/120 mmHg at day 3 of stroke onset) will be randomly allocated to therapy with
      olmesartan (20 mg/day) or nebivolol (5 mg/day) or no treatment between the 3rd to 7th day of
      hospitalization.
    
  